2
Views
1
CrossRef citations to date
0
Altmetric
Review

Premature Onset of Cardiovascular Disease in HIV-Infected Individuals: The Drugs and the Virus

, , , , , , & show all
Pages 675-692 | Published online: 14 Dec 2010
 

Abstract

Life expectancy in HIV-infected individuals has been greatly enhanced through immunologic restoration and virologic suppression resulting from antiretroviral therapy. Current clinical HIV care in Western countries focuses on treatment of drug toxicities and prevention of comorbidities. These non-AIDS HIV-related comorbidities, such as cardiovascular disease, occur even in individuals with virologic suppression and manifest at an earlier age than when normally presenting in the general population. While traditional risk factors are present in many HIV-infected individuals who develop cardiovascular disease, the additional roles of HIV-related chronic inflammation and immune activation as well as chronic HIV viremia may be significant. This review provides current evidence for the contributions of the virus, in terms of both chronic viremia and its contribution via chronic low-level inflammation, immune activation, premature immune senescence and dyslipidemia, to the pathogenesis of HIV-related cardiovascular disease, and balances this against the propensity of specific antiretroviral therapies to cause cardiovascular disease, in particular through altered cholesterol metabolism.

Financial & competing interests disclosure

Anna Maisa, Clare Westhorpe, Anthony Jaworowski, Anna C Hearps and Suzanne M Crowe are supported by the Australian Centre for Hepatitis and HIV Virology Research. Anna Maisa is supported by a fellowship within the Postdoc Programme of the German Academic Exchange Service (DAAD). Suzanne Crowe is an NHMRC Principal Research Fellow. Julian H Elliott is on advisory boards for Tibotec and ViiV Healthcare. Jennifer Hoy is on advisory boards of Bristol-Myers-Squibb, Gilead, Tibotec, Merck, Sharp & Dohme and ViiV. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

Anna Maisa, Clare Westhorpe, Anthony Jaworowski, Anna C Hearps and Suzanne M Crowe are supported by the Australian Centre for Hepatitis and HIV Virology Research. Anna Maisa is supported by a fellowship within the Postdoc Programme of the German Academic Exchange Service (DAAD). Suzanne Crowe is an NHMRC Principal Research Fellow. Julian H Elliott is on advisory boards for Tibotec and ViiV Healthcare. Jennifer Hoy is on advisory boards of Bristol-Myers-Squibb, Gilead, Tibotec, Merck, Sharp & Dohme and ViiV. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 419.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.